Table 3.
Univariate and Inverse Probability-Weighted Multivariate Survival Analysis
| Survival | Analysis | |
|---|---|---|
| Univariate, HR (95% CI) | Multivariate, aHR (95% CI)a | |
| Overall Survival | ||
| Age: continuous | 1.06 (1.03–1.10) | 1.06 (1.03–1.09) |
| Sex: male vs female | 2.03 (0.63–6.55) | |
| Race: white vs nonwhite | 1.12 (0.27–4.62) | |
| Comorbidity: Moderate to severe vs none to mild | 1.93 (0.99–3.79) | 0.92 (0.52–1.62) |
| Smoking: yes vs no | 4.30 (1.82–10.14) | 4.02 (1.94–8.30) |
| Pathological | ||
| T Stage:T3-T4 vs T1-T2 | 3.04 (1.70–5.43) | 1.38 (0.80–2.37) |
| N Stage: N2C-N3 vs N0-N2B | 2.06 (1.11–3.84) | 1.25 (0.75–2.08) |
| Adjuvant therapy: CRT vs RT | 1.05 (0.57–1.93) | 1.46 (0.91–2.33) |
| Disease-Free Survival | ||
| Age: continuous | 1.05 (1.02–1.08) | 1.04 (1.01–1.06) |
| Sex: male vs female | 1.81 (0.65–4.99) | |
| Race: white vs nonwhite | 1.37 (0.34–5.64) | |
| Comorbidity: Moderate to severe vs none to mild | 1.85 (0.98–3.51) | 0.77 (0.44–1.36) |
| Smoking: yes vs no | 3.42 (1.61–7.26) | 5.24 (2.55–10.78) |
| Pathological | ||
| T Stage: T3, T4 vs T1, T2 | 2.55 (1.47–4.43) | 1.31 (0.78–2.20) |
| N Stage: N2C-N3 vs N0-N2B | 1.87 (1.03–3.37) | 2.13 (1.34–3.40) |
| Adjuvant therapy: CRT vs RT | 0.93 (0.52–1.66) | 0.91 (0.59–1.42) |
Abbreviations: aHR, adjusted hazard ratio; CRT, chemoradiotherapy; HR, hazard ratio; RT, radiotherapy.
a
Inverse probability-weighted multivariate model included all variables significant in univariate analysis at the α level of 0.1 and adjuvant chemotherapy.